ITGAX and neoplasm: Flow cytometry analysis (Figure S3A) of tumor tissue after 2 weeks of AZD7507 treatment revealed a significant reduction in the frequency of F4/80+CD11b+ TAMs (Figures 3B and 3C), with no significant effect on Ly6C+ monocytes, CD11c+ dendritic cells, or Gr1+ cells (Figure 3C).